Previous 10 | Next 10 |
Gritstone bio ( NASDAQ: GRTS ) on Tuesday said its self-amplifying mRNA (samRNA) COVID vaccine showed tolerability and immunogenicity in two phase 1 trials. CORAL-CEPI : The study includes 340 people and is evaluating T cell-enhanced omicron- and beta-s...
Clinical-stage biotechnology company Gritstone bio ( NASDAQ: GRTS ) will sell 6.6M shares, through private investment in public equity financing, at $2.26 per share. The securities purchase agreement that the company has executed to sell also involves 13.3M pre-funded...
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private inve...
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good tolerability and immunogenicity in all vaccine-naïve subjects...
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims t...
Summary Gritstone bio results from the phase 1/2 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39% molecular response observed. Molecular response achieved in KRAS mutant NSCLC patients led to a doubling of overall surviv...
The following slide deck was published by Gritstone bio, Inc. in conjunction with this event. For further details see: Gritstone bio (GRTS) Presents at ESMO Congress 2022
Why The Stock Market Is Down Today The stock market is down today because of the latest round of August CPI data . The numbers came in higher than expected and what many hoped to be another month showing inflation was slowing became the stark reality that Fed Chairman Jerome Powell&...
Gritstone bio ( NASDAQ: GRTS ) said its SLATE vaccines (version 1 and SLATE-KRAS) showed early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC...
-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) -- -- Molecular response, as measu...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
-- Favorable progression-free survival (PFS) trend observed in preliminary data from the randomized Phase 2 study evaluating GRANITE (personalized neoantigen vaccine) in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC); mature PFS data expected in the third quarter of 2024...